Citations 1
FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).
Arriaga, Yull , Milowsky, Matthew I. , Currie, Graeme, Abella, Steve, Pal, Sumanta K. , Bellmunt, Joaquim , Picus, Joel , Kohli, Manish
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4534-4534
